Stenabolic (SR9009) is a synthetic compound studied as a REV-ERB agonist—a class of molecules that regulate circadian rhythm and metabolic activity at the cellular level. Research into SR9009 has focused on its potential role in energy metabolism, basal metabolic rate (BMR), and skeletal-muscle endurance within controlled experimental models.

Key Research Features

• Mechanism: REV-ERBα/β receptor agonism regulating circadian and metabolic pathways.
• Primary research focus: Studies on energy expenditure, lipid metabolism, and endurance performance in skeletal muscle models.
• Half-life: Approximately 2–4 hours (short-acting compound).
• Cycle observation window: Typically 8–12 weeks in reference sampling trials.

Research Overview

Pre-clinical literature suggests that Stenabolic (SR9009) enhances the metabolic rate of skeletal muscle by up-regulating genes involved in mitochondrial biogenesis and fatty-acid oxidation. These findings have made SR9009 a reference tool for evaluating metabolic rate modulation, endurance performance, and muscle energy utilization.

Product Specifications

• Compound: SR9009 (Stenabolic)
• Form: Oral reference tablets
• Strength: 10 mg per tablet
• Pack size: 56 tablets

Reference Sampling Protocol (Educational)

Reference Notes

• Dose division: Due to its 2–4-hour half-life, dosing should be evenly distributed across the day for stable observation values.
• Tablet splitting: Tablets may be divided into halves as indicated on packaging for accurate interval sampling.
• Hydration: Maintain adequate fluid intake throughout the study period.
• Stacking: Can be paired with other SARMs in multi-compound performance-metabolism research models.

Observed Outcomes (Reference Literature)

• Enhanced mitochondrial density and oxidative capacity in skeletal-muscle studies.
• Increased basal metabolic rate (BMR) and fat-oxidation efficiency under controlled conditions.
• Improved endurance capacity in murine and cell-culture models.
• Potential modulation of circadian gene expression affecting metabolism and recovery.

All outcomes derived from pre-clinical studies. Not intended for diagnostic or therapeutic use.

Observation Cycle & Handling

• Observation period: 8–12 weeks.
• Sampling frequency: 4–6 micro-doses daily, every 3–4 hours, due to short half-life.
• Rest interval: 2–3 weeks recommended between extended sampling cycles.
• Storage: Keep sealed and protected from light at room temperature (<25 °C).

What’s in the Box

• 56 × 10 mg Stenabolic (SR9009) reference tablets

Why Choose EU Pharmaceuticals?

EU Pharmaceuticals provides validated reference compounds for metabolic and androgen-pathway research. Each batch is HPLC and MS-verified to confirm purity, identity, and concentration accuracy for reproducible analytical outcomes.

For laboratory, educational, and research use only. Not for human or veterinary ingestion or therapeutic application. No medical or performance claims are made or implied. Buyer assumes responsibility for lawful handling and regulatory compliance.